Retinagenix Holdings, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Retinagenix Holdings, LLC - overview
Established
2020
Location
Palo Alto, CA, US
Primary Industry
Pharmaceuticals
About
Based in California, US, and founded in 2020 by Marco Northland, and David Saperstein, Retinagenix Holdings, LLC operates as a pharmaceutical company that develops zuretinol acetate (RGX 001) for the treatment of eye diseases such as pigmentosa and retinitis. In January 2022, Eluminex Biosciences Limited, a portfolio company of GL Ventures, Lilly Asia Ventures, and Quan Capital, acquired Retinagenix Holdings, LLC. Retinagenix is a privately held biotechnology company focused on meeting the significant and growing unmet medical needs in genetically determined orphan eye diseases that develop zuretinol acetate (RGX 001) for the treatment of eye diseases such as pigmentosa and retinitis.
Current Investors
Eluminex Biosciences Limited
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.retinagenix.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.